WuXi AppTec’s leadership played down concerns about reduced demand for glucagon-like peptide-1 receptor agonist (GLP-1RA) manufacturing after leading obesity player Eli Lilly released lower-than ...

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo ... Novo has struggled to stay competitive with Eli Lilly LLY in developing the next ...

The request follows a similar move by Eli Lilly, which has asked for a ban on ... professionals turning to unapproved versions of GLP-1 drugs as an option for weight loss, saying: "This can ...

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs by partnering with KeyBioscience in 2017. At one time, the Big Pharma was ...

Weaker than expected data from the trial was a blow to Novo’s ambitions to find a more powerful competitor to Lilly’s ... mimics gut hormone GLP-1, with a separate molecule called cagrilintide ...

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...